Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 4, 2013, Pages 490-498

  Copin, Jean Christophe ^a,b   Da Silva, Rafaela F ^c,d   Fraga Silva, Rodrigo A ^c,d   Capettini, Luciano ^c,d   Quintao, Silvia ^c,d   Lenglet, Sébastien ^b   Pelli, Graziano ^b   Galan, Katia ^b   Burger, Fabienne ^b   Braunersreuther, Vincent ^b   Schaller, Karl ^b   Deruaz, Maud ^e   Proudfoot, Amanda E ^f   Dallegri, Franco ^g   Stergiopulos, Nikolaos ^c   Santos, Robson A S ^d   Gasche, Yvan ^a,b   MacH, François ^b   Montecucco, Fabrizio ^b,g  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c EPFL   (Switzerland)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MERCK SERONO S A   (Switzerland)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

acute stroke; atherosclerosis; brain ischemia; carotid artery; inflammation

Indexed keywords

ALPHA CHEMOKINE; APOLIPOPROTEIN E; COLLAGEN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EVASIN 3; GELATINASE B; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HISTOPATHOLOGY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ANIMALS; ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN INJURIES; CAROTID ARTERY DISEASES; CHEMOKINE CXCL1; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; NEUTROPHILS; RECEPTORS, CXCR; STROKE;

EID: 84876411913     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.198     Document Type: Article

References (37)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3e442.
2. Centers for Disease Control and Prevention (CDC). Prevalence of stroke-United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2012; 61: 379-382.
3. Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuro-pharmacology 2008; 55: 250-256.
4. King A, Markus HS. Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis. Stroke 2009; 40: 3711-3717.
5. Elkind MS. Inflammation, atherosclerosis, and stroke. Neurologist 2006; 12: 140-148.
6. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 7: 97.
7. Mirabelli-Badenier M, Braunersreuther V, Viviani GL, Dallegri F, Quercioli A, Veneselli E et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2011; 105: 409-420.
8. Déruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008; 205: 2019-2031.
9. Montecucco F, Lenglet S, Braunersreuther V, Pelli G, Pellieux C, Montessuit C et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010; 30: 1371-1377.
10. Copin JC, Goodyear MC, Gidday JM, Shah AR, Gascon E, Dayer A et al. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur J Neurosci 2005; 22: 1597-1608.
11. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006; 113: 2744-2753.
12. Ardehali MR, Rondouin G. Microsurgical intraluminal middle cerebral artery occlusion model in rodents. Acta Neurol Scand 2003; 107: 267-275.
13. Hata R, Mies G, Wiessner C, Fritze K, Hesselbarth D, Brinker G et al. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 1998; 18: 367-375.
14. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289: H558-H568.
15. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472-476.
16. Li F, Irie K, Anwer MS, Fisher M. Delayed triphenyltetrazolium chloride staining remains useful for evaluating cerebral infarct volume in a rat stroke model. J Cereb Blood Flow Metab 1997; 17: 1132-1135.
17. Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix metallo-proteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 2008; 213: 196-201.
18. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-856.
19. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
20. Montecucco F, Bauer I, Braunersreuther V, Bruzzone S, Akhmedov A, Lüscher TF et al. Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2012; doi:10.1089/ars.2011.4487.
21. Kagiyama T, Glushakov AV, Sumners C, Roose B, Dennis DM, Phillips MI et al. Neuroprotective action of halogenated derivatives of L-phenylalanine. Stroke 2004; 35: 1192-1196.
22. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
23. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353-363.
24. Schmerbach K, Schefe JH, Krikov M, Mü ller S, Villringer A, Kintscher U et al. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Brain Res 2008; 1208: 225-233.
25. Cheng C, Tempel D, van Haperen R, de Boer HC, Segers D, Huisman M et al. Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines. J Clin Invest 2007; 117: 616-626.
26. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373-379.
27. Kitayama J, Faraci FM, Lentz SR, Heistad DD. Cerebral vascular dysfunction during hypercholesterolemia. Stroke 2007; 38: 2136-2141.
28. Crisby M, Rahman SM, Sylvén C, Winblad B, Schultzberg M. Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke. Neurosci Lett 2004; 369: 87-92.
29. d'Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein e-deficient mice. Stroke 2001 32: 2658-2664.
30. Connolly Jr ES, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209-216.
31. Wang G, Guo Q, Hossain M, Fazio V, Zeynalov E, Janigro D et al. Bone marrow-derived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Res 2009; 1294: 183-192.
32. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-1126.
33. Quercioli A, Mach F, Bertolotto M, Lenglet S, Vuilleumier N, Galan K et al. Receptor activator of NF-kB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost 2012; 107: 124-139.
34. Raz L, Zhang QG, Zhou CF, Han D, Gulati P, Yang LC et al. Role of Rac1 GTPase in NADPH oxidase activation and cognitive impairment following cerebral ischemia in the rat. PLoS One 2010; 5: e12606.
35. Murikinati S, Jüttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 2010; 24: 788-798.
36. Anthony DC, Walker K, Perry VH. The therapeutic potential of CXC chemokine blockade in acute inflammation in the brain. Expert Opin Investig Drugs 1999; 8: 363-371.
37. Brait VH, Rivera J, Broughton BR, Lee S, Drummond GR, Sobey CG. Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome. Brain Res 2011; 1372: 169-179.